NIPS regimen improves OS in gastric cancer with peritoneal metastasis
        12 Mar 2025
    byElaine Soliven 
        Among patients with gastric cancer and peritoneal metastasis, treatment with neoadjuvant intraperitoneal–systemic (NIPS) regimen, which consists of intraperitoneal (IP) and intravenous (IV) paclitaxel plus S-1, significantly improved overall survival (OS) compared with IV paclitaxel plus S-1 only (PS regimen), according to the DRAGON-01 trial presented at ASCO GI 2025.